Analyst Price Target is $6.75
▲ +341.18% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Compass Therapeutics in the last 3 months. The average price target is $6.75, with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 341.18% upside from the last price of $1.53.
Current Consensus is
Moderate Buy
The current consensus among 5 polled investment analysts is to moderate buy stock in Compass Therapeutics. This rating has held steady since October 2024, when it changed from a Buy consensus rating.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Read More
